| Name | Title | Contact Details |
|---|
Worldcare Limited is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Two things distinguish CHIA in our pursuit of improving the Massachusetts health care system: our public-interest perspective, and our unique data sets. Our perspective is rooted in our independence – our agenda and findings are not colored by the special interests of industry or politics – and in the talents and commitment of CHIA employees. CHIA`s mission is to be the agency of record for Massachusetts health care information, to responsibly steward sensitive and confidential data, and to objectively report reliable and meaningful information about the quality, affordability, utilization, access, and outcomes of the Massachusetts health care system. We pursue this mission in the public interest. This informs our objective perspective, and our commitment to serving a broad, diverse audience. We are a hub, connecting our products to policymakers, public and private payers and providers, employers, researchers, and the residents of Massachusetts. Our vision is a transparent health care system where reliable information provides common ground for improvement and empowers people and organizations to make informed decisions.
Novitas Solutions is a Camp Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Betz Mitchell Associates is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.